Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

CVS Health to Expand Access to Opioid Overdose-Reversal Drug for CVS Pharmacy Patients in Seven Additional States

Naloxone access to increase in NM, LA, FL, CO, ID, OR and WA this summer

Program to combat opioid epidemic will operate in total of 30 states by August


News provided by

CVS Health

May 25, 2016, 08:30 ET

Share this article

Share toX

Share this article

Share toX

WOONSOCKET, R.I., May 25, 2016 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced it will expand access to the opioid overdose-reversal drug naloxone in seven additional states this summer, contributing to a total of 30 states where the life-saving medication will be more accessible to CVS Pharmacy patients. CVS Health's naloxone program establishes a standing order with a physician in the state, which permits CVS Pharmacists to dispense naloxone to patients without an individual prescription. 

CVS Health experts discuss what consumers should know about the opioid overdose-reversing drug naloxone and preventing drug abuse
CVS Health experts discuss what consumers should know about the opioid overdose-reversing drug naloxone and preventing drug abuse
Naloxone is a drug that reverses the effects of an opioid overdose and will be available to patients without a prescription at CVS Pharmacy locations in 30 states
Naloxone is a drug that reverses the effects of an opioid overdose and will be available to patients without a prescription at CVS Pharmacy locations in 30 states
A CVS Pharmacist stocks the opoid-overdose reversal drug naloxone
A CVS Pharmacist stocks the opoid-overdose reversal drug naloxone
A CVS Pharmacist assembles naloxone kits
A CVS Pharmacist assembles naloxone kits
A CVS pharmacist provides information about how to identify an opioid overdose and properly administer naloxone when dispensing the medication
A CVS pharmacist provides information about how to identify an opioid overdose and properly administer naloxone when dispensing the medication
CVS Pharmacy patients can visit CVS.com for resources on proper medication use and disposal to prevent prescription drug abuse
CVS Pharmacy patients can visit CVS.com for resources on proper medication use and disposal to prevent prescription drug abuse
CVS Health logo
CVS Health logo
CVS Health experts discuss what consumers should know about the opioid overdose-reversing drug naloxone and preventing drug abuse
Naloxone is a drug that reverses the effects of an opioid overdose and will be available to patients without a prescription at CVS Pharmacy locations in 30 states A CVS Pharmacist stocks the opoid-overdose reversal drug naloxone A CVS Pharmacist assembles naloxone kits A CVS pharmacist provides information about how to identify an opioid overdose and properly administer naloxone when dispensing the medication CVS Pharmacy patients can visit CVS.com for resources on proper medication use and disposal to prevent prescription drug abuse CVS Health logo

Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7847151-cvs-health-opioid-reversal-expansion/

"Naloxone is a safe and effective antidote to opioid overdose and by expanding availability of this medication, we can save lives and give more people a chance to get the help they need for recovery," said Tom Davis, RPh, Vice President of Pharmacy Professional Practices at CVS Pharmacy. "By establishing a physician-authorized standing order that allows our pharmacies to dispense naloxone to patients without an individual prescription, we strengthen our commitment to helping the communities we serve begin to address the challenges of prescription drug abuse."

Expansion of the company's naloxone program will begin with New Mexico in late May; followed by Louisiana in early June; Florida in early July; Colorado, Idaho and Oregon in mid-July; and Washington in early August.  Naloxone is already available without a prescription at CVS Pharmacy locations through standing order or collaborative practice agreements in 23 states: Arkansas, California, Connecticut, Indiana, Kentucky, Maryland, Massachusetts, Minnesota, Mississippi, Montana, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Virginia and Wisconsin.

"Expanding access to the overdose-reversal drug naloxone is a critical part of our national strategy to stop the prescription drug and heroin overdose epidemic – along with effective prevention, treatment, and enforcement," said Michael Botticelli, Director of National Drug Control Policy. "Thanks to efforts on naloxone like those announced today by CVS Health, more Americans will have access to this lifesaving drug."

The move to expand access to naloxone builds on CVS Health's longstanding commitment to help communities address and prevent drug abuse through education, outreach and safe medication disposal. Patients visiting CVS.com can find recently launched drug abuse prevention resources for themselves and their families.  The company has also launched a community outreach program called Pharmacists Teach, which brings local pharmacists to high school health classes to talk to students about the dangers of drug abuse. More than 80,000 students have already been part of the program. High schools across the country can learn more about bringing Pharmacists Teach to their school here.

CVS Health has also joined with the Partnership for Drug-Free Kids for the Medication Disposal for Safer Communities Program, which has donated more than 500 drug disposal units to police departments around the country. The program gives members of the community a safe and environmentally friendly way to dispose of unwanted medication and has already collected more than 35 metric tons of prescription drugs. Police departments across the country can apply to receive a drug collection unit from the program here.

"CVS Health has been a leader in the work of helping communities prevent prescription drug abuse," said Marcia Lee Taylor, President and CEO, Partnership for Drug-Free Kids. "In addition to proper disposal of unwanted medication, increasing access to naloxone is a critical public health priority that allows patients and their families to prevent opioid fatalities and recognize when people need help working towards recovery from the disease of addiction."

About CVS Health:
CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contact:
Erin Shields Britt
Corporate Communications
401-770-9237
[email protected]

SOURCE CVS Health

Related Links

http://www.cvshealth.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medicare Advantage (MA) products with benefits and programs reflecting the...

CVS Health to hold third quarter 2025 earnings conference call

CVS Health to hold third quarter 2025 earnings conference call

CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, October 29th, 2025, at 8:00 a.m. ET to discuss third...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

New Products & Services

New Products & Services

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.